ABT Abbott Laboratories Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
Time
Author
Thesis
Company / ticker
Signal
Since call
Position
Source
20:14
Sep 26
Sep 26
r/ValueInvesting
Established profitable business with lower risk and upside
Author grades Abbott B+ with 8.0/10 conviction, favoring its long-established profitable business and considerably lower fundamental risk. Revenue has returned to growth and trailing net income is about $5.4B, so the exercise rewards probability and downside protection rather than explosive upside. Bull target $125 vs bear $85 over roughly 12–18 months; main risk is low-mid.
ABT
Abbott Laboratories
Long
1ST
—
—
23:51
Aug 17
Aug 17
CNBC
Abbott is cheap at 20 times earnings
Cramer disagrees with concerns about Abbott's acquisition, says Abbott is good, and at only 20x earnings it is still too cheap for Abbott. He would hold the stock.
ABT
Abbott Laboratories
Long
—
—
About ABT Investor Commentary
Across the available history and selected sources, Buzzberg tracks ABT (Abbott Laboratories) across 23 sources: 15 bullish vs 0 bearish calls from 33 authors. Historical directional balance: 23% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 64 total trade ideas tracked. Latest voices: u/Legitimate_Risk_1079, Jim Cramer.